3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Withdrawn
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gynecologic
1
Gastrointestinal
1
CNS
1
Breast
1
Conditions
Glioblastoma
3
Glioma
2
Diffuse Intrinsic Pontine Glioma
2
Astrocytoma
2
Triple Negative Breast Neoplasms
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Optic Nerve Glioma
1
Oligodendroglioma
1
Neoplasms
1
Neoplasm Metastasis
1
Medulloblastoma
1
Gliosarcoma
1
Colonic Neoplasms
1
Breast Neoplasms
1
Brain Stem Neoplasms
1
Brain Neoplasms
1
Interventions
pembrolizumab
3
Trastuzumab
2
Irinotecan
2
Cyclophosphamide
2
vocimagene amiretrorepvec
1
veliparib
1
sacituzumab govitecan
1
paclitaxel-Angiopep-2 conjugate
1
lenvatinib
1
irinotecan sucrosofate
1
iniparib
1
fludarabine
1
depatuxizumab mafodotin
1
cabozantinib
1
bintrafusp alfa protein, human
1
aldesleukin
1
Platinum
1
Nivolumab
1
NVP-BKM120
1
N-(2,3-dihydroxypropyl)-1-((2-fluoro-4-iodophenyl)amino)isonicotinamide
1
Metformin
1
Mebendazole
1
Ipilimumab
1
Interleukin-2
1
Flucytosine
1
Doxycycline
1
Cisplatin
1
Capecitabine
1
Atorvastatin
1
7-hydroxystaurosporine
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Triple Negative Breast Neoplasms
×
Mebendazole
×
CNS
×
Clear all
NCT02201381
2022-07-18
METRICS
Health Clinics Limited
Phase 3
Withdrawn